Axa’s Alaunos Therapeutics TCRT Stock Holding History

Axa’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,850	Closed	-$572K	–	1210
2022 Q1	$572K	Hold	5,850	–	–	﹤0.01%	1023
2021 Q4	$956K	Buy	+5,850	New	+$1.29M	﹤0.01%	954
2021 Q3	–	Sell	-402	Closed	-$159K	–	1319
2021 Q2	$159K	Buy	+402	New	+$188K	﹤0.01%	1231
2016 Q1	–	Sell	-1,558	Closed	-$1.94M	–	1411
2015 Q4	$1.94M	Buy	+1,558	New	+$2.58M	0.01%	776

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Axa's TCRT Position: Q2 2022 in Review

Axa sold out of Alaunos Therapeutics (TCRT) in Q2 2022, closing a stake of 5,850 shares — an estimated $572K sold.

Axa first reported a position in TCRT in Q4 2015 and held it in 4 quarters. The position peaked at $1.94M in Q4 2015. 124 funds tracked by Wall St. Rank hold TCRT as of Q2 2022.

Axa reported no remaining Alaunos Therapeutics position as of Q2 2022 after selling out during the quarter.
Axa sold 5,850 Alaunos Therapeutics shares in Q2 2022, an estimated $572K.
Axa first reported a position in Alaunos Therapeutics in Q4 2015 and held it in 4 quarters.
Axa's Alaunos Therapeutics position peaked at $1.94M in Q4 2015.
124 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2022.

Based on Axa's 13F filing for Q2 2022, filed 15 Aug 2022.